WO1999058721A1 - Amplification muliplex d'adn a l'aide d'amorces chimeres - Google Patents

Amplification muliplex d'adn a l'aide d'amorces chimeres Download PDF

Info

Publication number
WO1999058721A1
WO1999058721A1 PCT/US1999/010417 US9910417W WO9958721A1 WO 1999058721 A1 WO1999058721 A1 WO 1999058721A1 US 9910417 W US9910417 W US 9910417W WO 9958721 A1 WO9958721 A1 WO 9958721A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
primer
labeled
amplification
template nucleic
Prior art date
Application number
PCT/US1999/010417
Other languages
English (en)
Inventor
David G. Wang
Eric S. Lander
Original Assignee
Whitehead Institute For Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute For Biomedical Research filed Critical Whitehead Institute For Biomedical Research
Priority to AU39846/99A priority Critical patent/AU3984699A/en
Publication of WO1999058721A1 publication Critical patent/WO1999058721A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Definitions

  • Restriction fragment length polymorphisms and restriction site maps supplanted isozymes as the tools of choice in the 1980 's.
  • simple sequence length polymorphisms also called STRs, or Short Tandem Repeats
  • sequence tagged sites STSs
  • Single nucleotide polymorphisms SNPs are positions at which two alternative bases occur at appreciable frequency (>1%) in the human population, and are the most common type of human genetic variation. There is growing recognition that large collections of mapped SNPs would provide a powerful tool for human genetic studies.
  • SNPs can also be used to create more markers for genetic maps, or to study linkage disequilibrium, or human evolution and migration. Before SNPs can be systematically applied in such studies, however, it is necessary to create a large collection of such loci, construct maps of their genomic locations, and develop methods for large-scale genotyping.
  • the present invention relates to a method of multiplex amplification by which a large number of target sequences on a template nucleic acid are amplified simultaneously, and labeled for detection.
  • the primers are incorporated into the products.
  • the primers copy the target sequences on the template nucleic acid.
  • later cycles of the reaction however, the number of copies outnumbers (and later overwhelms) the number of original template sequences.
  • the primers begin to use the products from earlier cycles as template.
  • the template/target sequence is copied, as is the primer that was incorporated into the 5 ' end of the target/template during its production in the earlier cycle.
  • the products from these later cycles (which at the end of the reaction form the vast majority of the products) consist of target sequence located between the incorporated primers at the 5 ' end, and the complements of those primers at the 3' end.
  • the method of the invention makes use of chimeric primers, which are primers which have both a hybridization segment and a constant segment.
  • the hybridization segment hybridizes to the template nucleic acid so that extension by the polymerase can occur.
  • the constant segment does not hybridize with the original template nucleic acid. As products from earlier cycles are used as templates, however, this constant segment also hybridizes to the template. This normalizes the hybridization kinetics across the different target sequences being simultaneously amplified, preventing loci from being over or underrepresented at the end of the reaction.
  • the invention features a method for simultaneously amplifying a plurality of target sequences from template nucleic acid and labeling the amplification products, comprising the steps of (a) combining template nucleic acid and a plurality of pairs of chimeric primers under conditions appropriate for members of the chimeric primer pairs to hybridize to complementary nucleic acid sequences on the template nucleic acid sufficiently well to permit primer extension by a polymerase enzyme, thereby producing template-primer complexes, (b) subjecting the template- primer complexes to conditions appropriate for a first amplification reaction, thereby producing a set of first amplification products, (c) combining these first amplification products and a plurality of pairs of labeled primers, under conditions appropriate for members of the labeled primer pairs to hybridize to complementary nucleic acid sequences on the first amplification products sufficiently well to permit primer extension by a polymerase enzyme, thereby producing product -primer complexes, and (d) subjecting the product-primer complexes to conditions appropriate
  • the template nucleic acid can be isolated nucleic acid, isolated genomic DNA, cDNA, or nucleic acid not isolated away from other cellular components.
  • Each member of a chimeric primer pair includes a hybridization segment and a constant segment .
  • An example of a pair of constant segments is 5 ' -TAATACGACTCACTATAGGGAGA-3 ' (SEQ ID NO:l) for use on the forward primer and 5' -AATTAACCCTCACTAAAGGGAGA-3 ' (SEQ ID NO : 2 ) for use on the reverse primer.
  • the conditions include a high concentration of MgCl 2 ( e . g.
  • the labeled primers can be labeled with a biotin molecule, a fluorophore, a dye, a metal, or a radionuclide .
  • the labeled primers have constant segments identical to the constant segments of the chimeric primers used in the first amplification reaction. In this embodiment, amplification and detection are performed in two separate reactions.
  • the first reaction uses high levels of magnesium and low extension temperatures, and many (up to several hundred) pairs of chimeric primers, which are used to simultaneously amplify several hundred target sequences on a template nucleic acid.
  • Each chimeric primer includes a hybridization segment, which is nucleic acid which hybridizes to its complementary sequence on the template nucleic acid, and a constant segment, which is nucleic acid which does not hybridize to the template nucleic acid.
  • the hybridization segment is different for each chimeric primer and each pair of chimeric primers is designed so that the hybridization segment of each member of the pair hybridizes to a sequence on the template nucleic acid which flanks a target sequence.
  • each pair of chimeric primers hybridizes to the template nucleic acid, in regions which flank the target (a portion of the template nucleic acid to be amplified) ; each member of a chimeric primer pair hybridizes at one end of the target segment and, thus, together the pair of chimeric primers flank the target segment.
  • each target sequence is amplified by its own unique pair of chimeric primers. For example, ten primer pairs (twenty primers, each with a different hybridization segment) , are needed to amplify ten different target sequences. The hybridization segments of the primers are therefore used to amplify the target sequences on the template nucleic acid.
  • the first amplification reaction uses the chimeric primers to make copies of the target sequences . As these copies are made, the polymerase incorporates each chimeric primer into the copy being made.
  • a second amplification reaction follows, which labels the products from the first amplification reaction.
  • This second reaction uses labeled primers which hybridize to the complements of the constant segments located at the 3 ' ends of the amplification products .
  • the constant segments of the chimeric primers are chosen so as to comprise sequence that is unrelated to the template nucleic acid, and is therefore unlikely to hybridize with it.
  • chimeric primers used to amplify mammalian DNA for example, bacteriophage or insect sequences can serve as the constant segments.
  • two constant segments derived from bacteriophage are used.
  • One of the pair consists of the T7 promoter sequence 5' -TAATACGACTCACTATAGGGAGA-3 ' (SEQ ID NO:l), which is synthesized onto the 5' end of the 'forward' chimeric primer within each primer pair, and the other is the T3 promoter sequence 5 ' -AATTAACCCTCACTAAAGGGAGA-3 ' (SEQ ID NO:2), which is synthesized onto the 5' end of the 'reverse' primer.
  • two different labeled primers are used.
  • the first is a biotinylated T7 promoter sequence (5'-biotin- TAATACGACTCACTATAGGGAGA-3 ' , SEQ ID NO : 3 ) , which hybridizes to the amplification products produced by the chimeric primer containing the T3 promoter sequence (SEQ ID NO: 2) .
  • the second labeled primer is a biotinylated T3 promoter sequence (5 ' -biotin-AATTAACCCTCACTAAAGGG-3 ' , SEQ ID NO:4), which hybridizes to the amplification product produced by the T7 chimeric primer (SEQ ID N0:1) .
  • constant segment is used on all of the forward primers, and another constant segment is used on all of the reverse primers.
  • constant segments normalize hybridization across all of the different loci, that is, they provide for similar hybridization kinetics for the many loci being amplified simultaneously. This results in roughly equal amounts of products from each locus.
  • Use of the constant segments provide an additional advantage in that they are used for detection in the second amplification reaction.
  • a single sequence is used as the constant segment on all of the chimeric primers (rather than two sequences as in the embodiment above) .
  • the 'forward' and the 'reverse' chimeric primers have identical 5' tails, and a single labeled primer is, therefore, used to label the amplification products.
  • the first amplification reaction amplifies the sequences on the template nucleic acid and the second amplification reaction labels the reaction products from the first amplification reaction.
  • the combination of chimeric primers and reaction conditions allows the simul taneous amplification of hundreds of loci.
  • 558 loci have been successfully amplified with a 50% pass rate, 92 loci with an 85% pass rate, and 46 or 23 loci exhibited 90% and 92% pass rates, respectively.
  • An advantage of the invention is that these pass rates were achieved without further optimization. Alternatively, the conditions may be further optimized to achieve higher pass rates.
  • the invention also features a method for simultaneously amplifying a plurality of target sequences from template nucleic acid and labeling the amplification products, including the steps of (a) combining template nucleic acid and a plurality of pairs of labeled chimeric primers, under conditions appropriate for members of the labeled chimeric primer pairs to hybridize to complementary nucleic acid sequences on the template nucleic acid sufficiently well to permit primer extension by a polymerase enzyme, thereby producing template-primer complexes; and (b) subjecting the template-primer complexes to conditions appropriate for an amplification reaction, thereby producing a set of labeled amplification products.
  • the amplification conditions may include a high concentration of MgCl 2 ( e . g.
  • the template nucleic acid can be isolated nucleic acid, isolated genomic DNA, cDNA, or nucleic acid not isolated away from other cellular components.
  • Each member of a labeled chimeric primer pair includes a hybridization segment and a labeled constant segment.
  • the sequence of the constant segment can be 5--TAATACGACTCACTATAGGGAGA-3 ' (SEQ ID NO:l) for the forward primer and 5 ' -AATTAACCCTCACTAAAGGGAGA-3 ' (SEQ ID NO: 2) for the reverse primer) .
  • the constant segment can be labeled with a biotin molecule, a fluorophore, a dye, a metal, or a radionuclide .
  • amplification and labeling of the products are carried out in a single step.
  • the chimeric primers can be synthesized as described above, and labeled ( e . g. , biotinylated) at the 5' end.
  • the reaction conditions are as for the first amplification reaction, that is, the conditions include high concentrations of MgCl 2 and low extension temperatures.
  • the second amplification reaction is omitted.
  • the invention features a kit for simultaneously amplifying a plurality of target sequences from a template nucleic acid and labeling the amplification products.
  • the kit includes (a) a plurality of pairs of chimeric primers, and (b) at least one reaction mixture appropriate for use in amplification reactions. At least one of the reaction mixtures includes a high concentration of MgCl 2 ( e . g. , from about 2.5 millimolar to about 7.0 millimolar, about 5 millimolar) .
  • Each member of a chimeric primer pair includes a hybridization segment and a constant segment ( e . g.
  • kits containing the chimeric primer pairs and, optionally, reaction mixtures for practicing the method of the invention can contain a collection of primer pairs useful to amplify a particular set of target sequences on a template nucleic acid.
  • the invention has the advantage of allowing the simultaneous amplification of many (e . g. , several hundred) target sequences in a single reaction and of allowing for labeling of the mixture of products.
  • a variety of methods are available for detecting and analyzing these products.
  • Using size-based methods of detection e . g. , gels
  • the Examples below describe analysis by means of genotyping chips, which is a non-size-dependent method of analysis.
  • the kit of the invention also has an advantage in that it contains a collection of primer pairs chosen so as to yield a particular type of information.
  • the primer pairs can be chosen to detect susceptibility to a set of genetic diseases.
  • the primers can be selected to detect polymorphisms in target sequences in highly variable regions of DNA. The polymorphisms found in an individual ' s DNA in those variable regions can be compared to the polymorphisms found in DNA from crime scene evidence in those same regions. If the polymorphisms from the individual and the evidence are different, then the individual is excluded from the pool of possible suspects. If they are the same, the individual cannot be excluded.
  • the methods and kits of the present invention can be used in humans and non-humans.
  • the methods, primers and kits can be used to assay polymorphisms in animals for veterinary purposes.
  • sets of primers can be chosen to amplify target sequences known to be associated with susceptibilities to diseases with genetic components, or to detect known genetic defects in purebred animals such as dogs or horses.
  • Primer sets can also be chosen to assess levels of biodiversity in populations of animals, plants, or microorganisms.
  • kits of the invention can also be used to amplify sequences across species. For instance, chimpanzees and humans share approximately 99% sequence similarity.
  • the methods and kits of the invention can be used to locate those areas in which the 1% interspecific difference is located, thereby pinpointing the "evolutionary hotspots" responsible for species differentiation, and interspecific conserved regions, as well .
  • Kits can also be created to fingerprint proprietary biological material. For example, a set of primers can be chosen corresponding to specific genotypes known to exist in a protected crop cultivar. Assays of plants can be made according to the present invention, to determine if those plants correspond to the genotype of the patented cultivar. BRIEF DESCRIPTION OF THE DRAWINGS
  • Figure 1 is a schematic diagram illustrating the use of chimeric primers in the amplification and labeling reactions, and the products made.
  • Figures 2A and 2B are more detailed diagrams and flow charts illustrating the same process as depicted in Figure 1.
  • Figure 2A depicts the first ampli ication reaction
  • Figure 2B depicts the second amplification reaction (the labeling reaction) .
  • “Target” indicates the target sequence, whether on the template nucleic acid, or the amplification products.
  • "zzzz” is meant to indicate nucleic acid sequence outside of the area of interest.
  • the forward chimeric primer has the sequence 5 ' -GGGTAAT-3 ' , comprising the hybridization segment "TAAT” , and constant segment "GGG” .
  • the reverse primer (3 ' -GCCGTTT-5 ' ) has hybridization segment "CGGC” and constant segment "TTT” .
  • the labeled primers are 5 ' -biotin-GGG-3 ' (which hybridizes to the "CCC” amplified from (and therefore complementary to) the forward chimeric primer), and 3'- TTT-biotin-5 ' (which hybridizes to the "AAA” amplified from (and therefore complementary to) the reverse chimeric primer) .
  • Figure 3 is a diagram illustrating the relative relationships on the template nucleic acid among the various target sequences, chimeric primers and primer pairs, and labeled primers of the method of the invention.
  • Target 1 "target 2”, etc. denote the target sequences of SNP locus 1, 2, etc.
  • Hila “H2a”, etc. are the hybridization segments for the forward primers for target 1, target 2, etc.
  • “Ca” is the constant segment for all of the forward chimeric primers
  • “Cb” is the constant segment for all of the reverse chimeric primers.
  • Described herein is a method of multiplex amplification. Using this method, several hundred pairs of chimeric primers are used to simultaneously amplify several hundred target sequences on template nucleic acid.
  • two successive amplification reactions are performed. The first of the two amplification reactions uses high levels of magnesium, low extension temperatures, and pairs of chimeric primers to simultaneously amplify a large number ( e . g. , up to several hundred) target sequences on a template nucleic acid.
  • high levels of magnesium is meant at least 2.5 millimolar, preferably about 2.5 millimolar to about 7.0 millimolar, and more preferably about 5 millimolar.
  • a “low” extension temperature is meant, for a polymerase with a normally optimal extension temperature of 72 °C, an extension temperature of about 60°C to about 70°C, preferably about 60°C to about 65°C, and most preferably about 65°C.
  • the amplification enzyme should be subjected to a sub- optimal temperature during extension, so as to equalize amplification across all of the different primer parts in the reaction, and to prevent over-representation of the products of some loci over others.
  • the chimeric primers used in the method each contain a hybridization segment and a constant segment. The hybridization segment hybridizes to the template nucleic acid in the vicinity of a target sequence; the constant segment consists of a sequence which does not hybridize to the template .
  • a second amplification reaction follows, which uses labeled primers to detectably label the reaction products of the first amplification reaction.
  • the combination of chimeric primers and reaction conditions allows for the simul taneous amplification of a large number of loci.
  • 558 loci have been successfully amplified with a 50% pass rate
  • 92 loci have been amplified with an 85% pass rate
  • 46 or 23 loci with 90% and 92% pass rates, respectively.
  • Amplification refers broadly to a process for using a polymerase and a pair of primers for increasing the amount of a particular nucleic acid sequence, referred to as a target sequence, relative to the amount of that sequence initially present (on the template sequence) .
  • the process may be accomplished by the in vi tro methods of the polymerase chain reaction or ligase chain reaction, or others.
  • a target sequence is a sequence that lies between the hybridization regions of two members of a pair of primers and is amplified by them.
  • the target sequence generally exists as part of a larger “template” sequence; however, in some cases, a target sequence and the template are the same.
  • the template sequence may be an isolated nucleic acid or, alternatively, a nucleic acid which has not been separated away from the cellular components of the biological source from which it was obtained.
  • template sequence generally refers to the nucleic acid sequence initially present, the products from each amplification cycle are in fact used as template sequence in subsequent amplification cycles.
  • the template nucleic acid can be isolated by methods well known in the art.
  • nucleic acid is meant a length of DNA, RNA, cDNA, nucleic acids from mammals or other animals, plants, insects, bacteria, viruses, or other organisms.
  • nucleic acids referred to herein as “isolated” are nucleic acids substantially free of (i.e., separated away from) the cellular components of the biological source from which they were obtained ( e . g. , as it exists in cells or in a mixture of nucleic acids such as a library) , which may have undergone further processing.
  • isolated nucleic acids include nucleic acids obtained by methods described herein, similar methods or other suitable methods, including essentially pure nucleic acids, nucleic acids produced by chemical synthesis, by combinations of biological and chemical methods, and recombinantly produced nucleic acids which are isolated (see e . g. , Daugherty, B.L. et al .
  • the template nucleic acid can therefore be a mixture of different nucleic acids or can be lengths of nucleic acid which are approximately the same ( e . g. , many copies of the same nucleic acid, such as nucleic acids which have been chemically synthesized or recombinantly produced) .
  • the template may occur as nucleic acid which has not been isolated from other cellular components, but has been treated in such a way that it is available for hybridization with amplification primers.
  • cells containing the template DNA can be denatured at high temperature to break the cellular membranes and expose the nucleic acids, and the primers and amplification reaction ingredients added directly to the denatured cellular
  • a "primer” is a length of single-stranded nucleic acid, which is used in combination with a polymerase to amplify a region from a template nucleic acid. Primers are generally short (e.g., 15-30 bases), but can be longer if required. The primer must contain a sequence which hybridizes with the template nucleic acid under the conditions used. Primers may be used singly, that is, a single primer consisting only of a single sequence can be used in the amplification reaction, and will produce one copy of one strand of the template per cycle of amplification.
  • a pair of primers is used in an amplification reaction.
  • the two are of different sequences, and are used in combination, and produce a copy of each template strand per cycle of amplification.
  • the two different primers should not be complementary to each other, or they will hybridize to each other rather than the template, and the polymerase will then be unable to make a copy of the template.
  • the two primers are chosen from sequence at the 5 ' end of each of the two complementary strands of the template nucleic acid.
  • a “chimeric primer pair” is a set of two chimeric primers wherein the hybridization segments each hybridize to the template sequence on opposite flanks of the target sequence.
  • a “chimeric primer” is a primer ( e . g. , a short piece of single-stranded nucleic acid) used for amplification of a target nucleic acid, wherein the primer contains a sequence (i.e., the "hybridization segment") which hybridizes to the template nucleic acid in the vicinity of the target sequence, and a sequence which does not hybridize to the template nucleic acid.
  • the method of the invention uses chimeric primers comprising a hybridization segment and a constant segment.
  • the constant segment should not hybridize to other constant segments, or to the hybridization segments of the chimeric primers .
  • the constant segment is generally about 15 to about 35 base pairs, such as about 20 to about 25 base pairs, about 15 to about 25 base pairs, about 15 to about 30 base pairs, about 20 to about 30 base pairs, about 15 to about 35 base pairs, about 20 to about 35 base pairs, about 25 to about 35 base pairs, or about 30 to about 35 base pairs.
  • the hybridization segments of the members of a given chimeric primer pair should have approximately the same T m . That is, all of the segments that hybridize with the template will have melting temperatures within degrees of each other.
  • the hybridization segments are selected by methods commonly known in the art of nucleic acid amplification. That is, the hybridization segment is analogous to, and serves the same purpose as, the primer as it is commonly used in the art of nucleic acid amplification, and it is selected in the same way.
  • the sequence of the target nucleic acid must be approximately known (e.g., it has been sequenced in the organism being studied, or in a related organism) . A short stretch of sequence at either end of the target is then selected to serve as the primer.
  • the two primers which are intended to amplify a specific target are chosen on the basis of several characteristics, including length (e.g., 15-35 base pairs is common in the field), melting temperature, or other criteria. For instance, depending on the sequence at one end of the target, it may be necessary to choose a longer or shorter primer in order to obtain a melting temperature to match the primer at the other end of the target sequence.
  • selection criteria are known in the field of nucleic acid amplification, and computer programs are available (e.g., PRIMER (Daly, M.J., Lincoln, S.E., and Lander, E.S., unpublished); Lerman, L.S., and Silverstein, K. , Meth. Enzymol .
  • the method of the invention uses two constant segments, the first comprises the T7 promoter sequence (5' -TAATACGACTCACTATAGGGAGA-3 ' , SEQ ID N0:1), which is synthesized onto the 5' end of the 'forward' primer.
  • the second constant segment comprises the T3 promoter sequence (5 ' -AATTAACCCTCACTAAAGGGAGA-3 ' , SEQ ID NO: 2), which is synthesized onto the 5 ' end of the reverse primer.
  • these constant segments were chosen from T3 and T7 sequences, sequences from other organisms (e.g., insects, reptiles) might also prove useful, so long as those sequences generally lack the ability to hybridize with mammalian DNA.
  • mammalian sequences might be used as the constant segments in situations where one wishes to construct chimeric primers to amplify non-mammalian template.
  • Primers in later amplification cycles increasingly use the products from previous cycles as template, so that at the end of the reaction, the majority of the amplification products consist of sequences which terminate at the 5' ends in the primer sequences ( Figure 1 and Figures 2A and 2B (boxes) ) .
  • the 3 ' ends of the products terminate with the complement of the chimeric primer ( Figures 2A and 2B (dashed boxes) ) .
  • the method of the invention uses chimeric primers with a non- hybridizing sequence at the 5' end, resulting in reaction products terminating in the constant sequences ( Figure 2A, "Products after successive amplification cycles") .
  • the method of the invention uses a second amplification reaction to label the reaction products of the first reaction ( Figure 2A) .
  • Labeled primers are used in this reaction.
  • a "labeled primer” is a primer (e.g., a short segment of single-stranded nucleic acid) which has a detectable label (e.g., biotin, fluorophore, radioactivity, heavy metals, dyes, etc.) attached to it.
  • Two primers are used in this method: 5 ' -biotin- TAATACGACTCACTATAGGGAGA-3' (SEQ ID NO : 3 ) , and 5 ' -biotin- AATTAACCCTCACTAAAGGG-3 ' (SEQ ID NO:4). These hybridize with the constant segments of the chimeric primers, and the products of this second reaction also have the primers incorporated into them. These primers are labeled however, and the products are therefore detectable .
  • Figure 1 presents a simplified illustration of one embodiment of the method, which uses two separate amplification reactions.
  • the first amplifies the targets.
  • the products from this reaction are then detectably labeled in the second reaction.
  • the target is flanked by two sequences (“ATTA” and "CGGC”) which are recognized by the hybridization segments on the chimeric primers ("TAAT” and "GCCG”) .
  • the constant segments of the chimeric primers do not hybridize with the template.
  • the target is copied from the 3' end of the chimeric primer. During the next cycle of amplification, this copy of the target also serves as a template. Unlike the original template nucleic acid however, this target/template is truncated at the 5 ' end, ending in the chimeric primer that was incorporated into the target/template during the previous cycle of amplification. These target/templates which are truncated at the 5 ' ends are then used as templates in the next cycle. The products of this next cycle are truncated at the 3 ' end, as well as the 5 ' end ( Figure 2B) .
  • Figure 3 illustrates the relationships on the template nucleic acid of the target loci, the chimeric primers, and the hybridization and constant segments.
  • the template nucleic acid is depicted by the thin horizontal line, and the target loci (e.g., "target 1", “target 2", etc.) are symbolized by heavier bars on the template.
  • “H” denotes a hybridization segment
  • “C” a constant segment.
  • “HI” and “Cl” are the hybridization and constant segments for a chimeric primer intended to amplify "target 1", for example.
  • the suffix “a” designates that the chimeric primer is the "forward” primer, and "b” indicates the "reverse” primer.
  • the method of the invention uses high levels of magnesium and low extension temperatures for the first amplification reaction, and more standard conditions for the labeling reaction.
  • a 50 ⁇ l reaction volume should contain between approximately 20 and 200 ng of template nucleic acid (preferably 100 ng) , about 0.1 to about 1.0 ⁇ M of each chimeric primer each chimeric primer should be at about 0.1 to 1.0 micromolar concentration, (preferably 0.5 to 1.0 ⁇ M) , about 1 unit of amplification enzyme, about 0.5 to about 2.0 mM dNTPs (preferably 1 mM) , about 10 mM Tris-HCl (pH 8.3), about 5 mM KC1, about 2.5 to about 7.0 mM MgCl 2 (preferably 5 mM) , and about 0.001% gelatin.
  • the hybridization segments of the chimeric primers are selected so as to have a T m (melting temperature) of about 55°C to about 60°C, with a preferred T m of about 57°C.
  • T m melting temperature
  • an annealing temperature of about 50°C to about 57°C is preferred, and the extension temperature should be about 70°C to about 60°C, preferably about 65°C.
  • the ingredients are at concentrations commonly used by those of skill in the art, and the temperature conditions are likewise as those commonly used.
  • the second amplification reaction could be omitted if the chimeric primers themselves were labeled (i.e., if each chimeric primer comprised a hybridization segment and a labeled constant segment) . If the constant segments of the chimeric primers were labeled (if the 5' ends of the chimeric primers were biotinylated, for example) , then the first amplification reaction would simply create labeled amplification products.
  • such a labeled constant segment could comprise the biotinylated T7 promoter sequence (5 ' -biotin-TAATACGACTCACTATAGGGAGA-3 SEQ ID NO: 3), added to the 5' end of the hybridization segment of the 'forward' primer.
  • the second constant segment would comprise a labeled T3 promoter sequence (5' -biotin-AATTAACCCTCACTAAAGGGAGA-3 ' , SEQ ID NO : 4 ) , added to the 5' end of the reverse primer.
  • T3 promoter sequence 5' -biotin-AATTAACCCTCACTAAAGGGAGA-3 ' , SEQ ID NO : 4
  • loci When multiplexing (amplifying many loci simultaneously) , it is imperative to be able to correctly differentiate between the amplification products from different loci. There are two commonly- used methods of accomplishing this; (1) size discrimination, or (2) on the basis of differentially labeling the reaction products.
  • the first method is most commonly done with detection methods which separate on the basis of size (e.g., gels) .
  • detection methods which separate on the basis of size (e.g., gels) .
  • loci to amplify together based on the ability of those loci to create products of different sizes, e.g., locus 1 creates a product of 100 bp, locus 2 creates a 200 bp, etc. Choosing which loci to amplify together is labor- intensive and requires careful planning.
  • the second method differentially labeling the reaction products, generally involves the attachment of different tags onto the primers for different loci .
  • Fluorescent tags are the most commonly used because one can use molecules which fluoresce at different wavelengths, with the result that amplification products from different loci fluoresce in different colors. This method is limited, however, by the number of different fluorescent molecules available on the market .
  • Hybridization to one of the oligonucleotides indicates that the sample is positive for that oligonucleotide sequence (Fodor, S.P.A. et al . , Science 251:767-773 (1991)). If aligned, overlapping sequences are arrayed (e.g., ABC, BCD, CDE, etc.), then the chip can be used for sequencing (Pease, A.C. et al . , Proc. Natl. Acad. Sci . USA 91:5022-5026 (1994)). Alternatively, the chip can contain oligonucleotides corresponding to polymorphic alleles (Chee, M. et al . , Science 274:610-614 (1996)).
  • oligonucleotides corresponding to those ten alleles can be placed on a genotyping chip. Hybridization to one of the alleles indicates that the sample is positive for that allele (see Example 2, "Design of Genotyping Chips, " infra) .
  • the hybridization segments of the chimeric primers are chosen so as to produce relatively short target sequences (e.g., 70-80 base pairs) .
  • Amplification products of such similar lengths would be extremely difficult to differentiate by size separation methods (e.g., electrophoretic gels), but are well -suited to detection by genotyping chips, or other size-insensitive detection methods.
  • the method of the invention also allows for the simultaneous detection of many polymorphisms in a sample.
  • a "polymorphism” is, fundamentally, an allelic variation between the nucleic acids of two samples. Such variations can range from gross morphological differences to differences in biochemistry, conformation of biomolecules, or differences in nucleic acid sequences.
  • the "samples” being examined can be whole organisms, or portions thereof, and can represent single individuals, or pooled populations. Polymorphisms include differences in nucleotide sequence, mutations, insertions, deletions, point mutations, or structural differences, as well as strand breaks or chemical modifications that result in an allelic variant in the form of a mismatch.
  • a polymorphism between two nucleic acids can occur naturally, or be caused by exposure to or contact with chemicals, enzymes, or other agents, or can be caused by circumstances which cause damage to nucleic acids (e.g., exposure to ultraviolet radiation, mutagens or carcinogens) .
  • SNPs single nucleotide polymorphisms
  • two sequences being compared may differ at more than a single nucleotide position. If the second difference occurs within the region where a primer should hybridize, that primer will not hybridize, and no reaction will occur. If the two differences both occur within the region that is amplified, aberrant patterns will be seen during the detection. In either case, it will be clear that the locus must be investigated further.
  • DNA polymorphism can be used to trace inheritance of disease genes in pedigrees (Lander, E.S. and Schork, N. , Science 265:2037-2048 (1994)).
  • geneticists had primarily employed restriction fragment length polymorphisms (RFLPs) during the 1980s and simple sequence length polymorphisms (SSLPs or microsatellites) during the 1990s. Both of these methods assay length differences by gel electrophoresis .
  • SNPs are now being seen as an attractive alternative for the future, because there exist a variety of assays that may allow greater automation, parallelism, and throughput than can be achieved with length measurement (Conner, B.J. et al . , Proc. Natl.
  • SNPs have only two alleles and thus are less informative than typical multi-allelic SSLPs, but this deficiency can be offset by greater density: a genome scan with 1,000 well-spaced SNPs will extract roughly the same linkage information as the current standard of 400 well-spaced SSLPs (Kruglyak, L., Nat. Genet. 17:21-24 (1997)). In addition, as shown below, SNPs can be assayed more efficiently than SSLPs, thereby providing a true advance over SSLP methodology.
  • Linkage Disequilibrium Mapping extends genetic analysis from families to populations by using high density genetic maps to recognize chromosomal segments descended from a common ancestor (Lander, E.S. & Botstein, D., Cold Spring Harbor Symp . Quant. Biol . 51:49-61 (1986)). Such analyses are useful in determining the location of a chromosomal segment conferring disease susceptibility. Ancestral segments that occur significantly more often in affected individuals are likely to harbor a susceptibility allele. The precise SNP density required to detect linkage disequilibrium varies with the age and structure of the population.
  • cSNPs coding-region SNPs
  • the invention has the advantage of allowing the simultaneous amplification of many (e.g., several hundred) target sequences in a single reaction, and of allowing for labeling of the mixture of products.
  • Kits can be made for use with the method of the invention. Such kits would contain pairs of chimeric primers intended to label specific target sequences on the template nucleic acid of an organisms or organisms, and also labeled primer pairs to label the amplification products. If the chimeric primers in the kit have a single constant segment (rather than two; i.e., one for the forward primer, and one for the reverse) , then only a single labeled primer need be included. Components for the two different amplification reactions may also be included (e.g., amplification reaction buffers, polymerase, etc.) . If the amplification and labeling are done in a single reaction, then reaction components for only that single reaction need be included.
  • amplification reaction buffers e.g., amplification reaction buffers, polymerase, etc.
  • the methods and kits of the invention can be used in any situation where it is desirable to amplify a large number of target sequences, regardless of whether or not they contain a polymorphism. For instance, primers can be chosen to amplify regions thought to be conserved, in order to rapidly identify individuals polymorphic in those regions.
  • the methods and kits of the invention can also be used to evaluate interspecific polymorphism (such as between humans and chimpanzees) to locate both conserved regions and also "hotspots" of evolutionary change .
  • the method and kits of the invention can be used for forensic identification of individuals.
  • Primer pairs can be selected to detect polymorphisms in target sequences in highly variable regions of DNA.
  • the polymorphisms found in a suspect's DNA in those variable regions can be compared to the polymorphisms found in DNA from crime scene evidence in those same regions .
  • Matching polymorphisms includes the suspect in the pool of possible perpetrators, while differing polymorphisms excludes the suspect.
  • biometrics is the identification and verification of individuals via a unique biological profile. Potential applications of biometrics include the identification of deceased persons, verification of identities of prisoners slated for release, or verification of a person's access to sensitive information or areas.
  • the kit of the invention has an advantage in that it can be assembled to contain a collection of primer pairs chosen so as to yield a particular type of information.
  • the primer pairs can be chosen to detect susceptibility to a genetic disease or set of diseases, or the presence of pathogens or parasites. Chromosomal deletions known to lead to cancer or other diseases can also be detected in this manner .
  • the methods and kits of the present invention can be used in humans and non-humans.
  • the methods, primers and kits can be used to assay sequences in animals for veterinary purposes (e.g., presence of pathogens or parasites) .
  • Sets of primers can be chosen to amplify target sequences known to be associated with susceptibilities to diseases with genetic components, or to detect known genetic defects in purebred animals such as dogs or horses.
  • kits can also be chosen to assess levels of biodiversity in field populations of animals, plants, or microorganisms. Individual organisms can also be "fingerprinted” and later re- identified, e.g., in animal migration studies, for instance. These same kits can also be used to study the evolution and migration of animal and plant populations. Kits can also be created to fingerprint proprietary biological material, such as microbiological strains, crop cultivars, or animals. For example, a set of primers can be chosen corresponding to highly variable regions known to exist in a protected crop cultivar. Assays of plants can be made according to the present invention, to create unique genetic profiles, and to determine if those plants correspond to the genotype of the patented cultivar. Parentage of purebred animals can also be verified in this way.
  • the SNP survey by gel -based sequencing examined three unrelated individuals (K104-1, K884-2, K1331-1) and a pool of ten individuals (K104-13, -14, -15, -16; K884-15, -16; K1331-12, -13, -14, -15) .
  • STSs were amplified with their corresponding amplification primers as described in Hudson, T.J. et al . (Science 270:1945-1954 (1995)) and Dietrich et al . (Dietrich, W. F. et al . , Nature 380:149-152 (1996); Dietrich, W. F. et al . , Nature Genetics 7:220-245; Dietrich, W. et al . , Genetics 131:423-447 (1992)), which are herein incorporated by reference in their entirety.
  • the forward primer was modified to include the M13 -21 primer site 5 ' -TGTAAAACGACGGCCAGT-3 ' (SEQ ID NO: 5) at its 5 '-end.
  • the resulting amplification products were subjected to dye-primer sequencing (Koontz, W.L.G. and Fukunaga, K. , IEEE Trans. Comp . , C-21, 171-178 (1972), herein incorporated by reference in their entirety) , with products detected on an ABI377 or ABI373 fluorescence sequence detector. Possible sequence variations were detected by the ABI Sequence Navigator software package, which suggests potential heterozygotes by identifying nucleotide positions at which a secondary peak exceeds a selected threshold of 50%. Such apparent variations were then visually inspected, to compare the patterns seen among the several individuals.
  • SNPs were obtained by surveying sequence-tagged sites (STSs) distributed across the human genome. These STSs are short genomic sequences, each with a corresponding amplification assay. An initial collection of 1,139 STSs was chosen from among the 24,568 STSs that had been used in the construction of a physical map of the human genome at the Whitehead/MIT
  • STSs contain a total of 279 kb of genomic sequence between all of the amplification primer sites, with one-third consisting of random genomic sequence and two-thirds of 3 ' -ends of expressed sequence tags (3 ' -ESTs) and primarily representing untranslated regions of genes .
  • Each STS was amplified from four samples: three of the samples were individual human DNAs and the fourth was pooled DNA from ten individuals.
  • Candidate SNPs were declared when two alleles were seen among the three individuals, with both alleles present at a frequency greater than 30% in the pooled sample.
  • the term 'candidate SNP' is used because a subset of such apparent polymorphisms turn out to be sequencing artifacts, as discussed below in Example 3, infra .
  • the survey found 279 candidate SNPs, corresponding to a rate of one SNP per 1001 base pairs screened and an observed nucleotide heterozygosity of 3.96 x 10 "4 (Table 1) .
  • the SNPs were distributed among 239 STSs, with some containing more than one polymorphic site.
  • the ratio of transitions to transversions was 2:1.
  • the dinucleotide CpG comprises only about 2% of the sequence surveyed, nearly 25% of the SNPs occurred at such sites with the substitution nearly always being C ⁇ ->T.
  • Cytosine residues within CpG dinucleotides are well known to be the most mutable sites within the human genome, because most are methylated and can spontaneously deaminate to yield a thymidine residue (Cooper, D.N. & Karwczak, M. , Hum. Genet. 85:55-74 (1990)).
  • 23 insertion/deletion polymorphisms were also found (with all but eight involving a single base) , corresponding to a frequency of one per 12 kb surveyed. Table 1: Results of SNP screening
  • SNPs were isolated by using two directed approaches using public databases. First, reports in the literature of common variants in gene coding regions were collected. Out of 143 cases tested, 121 variants were confirmed by the detection of two alleles in the four-sample screening panel described above. The remaining 22 reported variants may be true polymorphisms, but simply monomorphic in the individuals tested.
  • GenBank database which contains multiple entries for some ESTS. Such entries were compared to identify single-nucleotide differences, which might reflect either common polymorphisms or sequencing errors in single-pass EST sequencing. 200 such apparent differences were tested and the presence of a SNP was confirmed in 93 cases. These two directed approaches thus yielded an additional 214 SNPs.
  • a target DNA sequence of length L can be screened for polymorphism by hybridizing a biotin-labeled sample to a variant detector array (VDA) of size 8 x L.
  • VDA variant detector array
  • the array has four 25-mer probes complementary to the sequence centered at the position. The four differ only in that the central (13th) position is substituted by each of the four nucleotides.
  • Individuals that are homozygous for the expected sequence e.g., "A-A” should hybridize more strongly to the perfectly complementary probe than to the three probes containing a central mismatch.
  • VDA thus signals the presence of a sequence variant and, m many cases, indicates the nature of the change.
  • VDAs have been used previously for mutation detection of small, well-studied DNA targets m large numbers of samples, including 387 base pairs from the HIV-1 genome, 3.5 kb from the BRCA1 gene, and 16.6 kb from the human mitochondrion (Chee, M. et al .
  • the STSs were examined m seven unrelated individuals (K104-1, -16, K884-2, -15, -16, K1331-12, - 13), chosen from the CEPH pedigrees K104 (Amish) , K884 (Venezuelan) , and K1331 (Utah) . Altogether, this represented a survey of about 14 Mb of genomic sequence. For each chip, the corresponding STSs were amplified from an individual, pooled together, biotm-labeled, hybridized and stained as follows.
  • Amplification products intended for hybridization to the same chip were pooled together for subsequent processing. Approximately 1-2 ⁇ g of the pooled amplification product was purified with Qiaquick purification kit (Qiagen, Hilden, Germany) , fragmented with DNAse I, then biotin-labeled with terminal deoxynucleotidyl transferase (TdT, Life Technologies, GibcoBRL, (Gaithersburg, Maryland) , according to the manufacturer's instructions.
  • Qiaquick purification kit Qiagen, Hilden, Germany
  • TdT terminal deoxynucleotidyl transferase
  • the fragmentation was performed in a 40 ⁇ l reaction with 0.2 unit of DNase I (Promega, Madison, Wisconsin) , 10 mM Tris-acetate (pH 7.5) , 10 mM magnesium acetate, and 50 mM potassium acetate at 37°C for 15 minutes, after which the reaction was stopped by heat inactivation at 96°C for 15 minutes.
  • the terminal transferase reaction was performed by adding 15 units of TdT and 12.5 mM biotin-N6-ddATP (DuPont-NEN Products, Boston, MA) to the preceding reaction mixture, incubating at 37°C for 1 hour and then heat-inactivating at 96°C for 15 minutes.
  • the labeled samples were hybridized to the chip as follows.
  • Chips were denatured at 96°C for 5-6 minutes and cooled on ice for 2-5 minutes. Chips were pre-hybridized with 6X SSPET (0.9 M NaCl , 60 mM NaH 2 P0 4 , 6 mM EDTA (pH 7.4), 0.005% Triton X-100) for approximately 5 minutes and then hybridized with the denatured sample in hybridization buffer (3M tetramethylammonium chloride, 10 mM Tris-HCl (pH 7.8), 1 mM EDTA, 0.01% Triton X-100, 100 mg/ml herring sperm DNA, and 200 pM control oligonucleotide) at 44°C for 15 hours on a rotisserie at 40 RPM.
  • 6X SSPET 0.9 M NaCl , 60 mM NaH 2 P0 4 , 6 mM EDTA (pH 7.4), 0.005% Triton X-100
  • hybridization buffer 3M
  • Chips were washed 3 times with IX SSPET and 10 times with 6X SSPET at 22°C, then stained at room temperature with staining solution (2 mg/ml streptavidin R-phycoerythrin (Molecular Probes, Eugene, Oregon) and 0.5 mg/ml acetylated BSA in 6X SSPET) for 8 minutes. After staining, chips were washed 10 times with 6X SSPET at 22°C on a fluidics workstation (Affymetrix, Santa Clara, California) .
  • Hybridization to the chip was detected by using a confocal chip scanner (HP/Affymetrix, Santa Clara, California) with a resolution of 40-80 pixels per feature and a 560 nm filter, and visual inspection. At each position, samples were classified as homozygous for the expected sequence, homozygous for an alternative sequence, or heterozygous. A collection of 2,748 candidate SNPs was identified, corresponding to a rate of one per 721 base pairs surveyed and an observed nucleotide heterozygosity of 4.58 x 10 "4 (Table 1, supra) . The number of STSs containing SNPs was 2,299. The SNPs had a mean heterozygosity of 33%, with the minor allele having a mean frequency of 25%. SNPs were found less often in 3 ' -ESTs than in random genomic sequence (p ⁇ 0.023, one-sided).
  • the nucleotide heterozygosity rate was indistinguishable from the estimate obtained from gel -based sequencing in Example 1, above (p > 0.12, two-sided test) .
  • the ratio of transitions to transversions and the proportion of SNPs occurring at CPG dinucleotides were also indistinguishable.
  • the frequency of SNPs was higher in the chip-based survey because more samples (14 vs. 6 haploid genomes) were surveyed .
  • False positive rates were estimated by retesting candidate SNPs by thorough multipass gel -based sequencing. In the single-pass gel -based sequencing, 16% of the 120 candidate SNPs proved to be false positives, compared to 12% of the 220 candidate SNPs found in the chip-based survey. False negative rates were estimated by including a subset of STSs in both surveys. Fifty- five SNPs were identified with both of the two survey methods, and were carefully confirmed to eliminate false positives. Eight (15%) of the 55 were missed by single-pass gel -based resequencing and seven (13%) missed by the chip-based survey.
  • candidate SNPs should be confirmed before being regarded as certain.
  • Genotyping Chips for Multiplex Amplification Efficient methods are required for large-scale genotyping of SNPs, and one approach is to extend the use of chip-based re-sequencing from SNP discovery to SNP genotyping (Cronin, M.T. et al . , Hum. Mutation 7:244-255 (1996) ) .
  • Genotyping chips containing 'genotyping arrays' were synthesized for each SNP to be tested.
  • Each genotyping array consists of two short VDAs corresponding to the two alternative alleles. The presence of an allele is reflected in strong hybridization to the corresponding resequencing array.
  • Amplification assays were designed for the region containing each SNP, with the goal of being robust and mutually compatible.
  • primers were chosen using the PRIMER software package (Hudson, T.J. et al., Science 270:1945-1954 (1995)) to closely flank the polymorphic base and to have a predicted melting temperature of 57°C. Forward and reverse primers were synthesized with the T7 (5' -TAATACGACTCACTATAGGGAGA-3 ' , SEQ ID NO:l) and T3 (5 ' -AATTAACCCTCACTAAAGGGAGA-3 ' , SEQ ID NO : 2 ) promoter sites at their respective 5 '-ends.
  • Primer pairs were individually tested to determine if it produced a single clear fragment visible by agarose gel electrophoresis and ethidium bromide staining, as described in Hudson et al . (Science 270:1945-1954 (1995)). Amplification assays passing this test were further classified as being “strong” or “weak, " according to the yield of the fragment produced. Primer pairs were grouped into multiplex sets, with the sets chosen to consist of either all strong assays or all weak assays.
  • the most complex genotyping chip tested contained genotyping arrays for 558 candidate SNPs identified in the chip-based survey. Initially, the 558 loci were separately amplified, then pooled, labeled and hybridized to the chip. To determine whether each locus could be reliably read, a formal 'detection test' was defined: a locus passed if, for each of three individuals tested, the expected DNA sequence could be successfully read on both strands for one or both alleles. In all, 98% of the loci passed this detection test, with the remaining ten failing due to weak hybridization or cross-hybridization.
  • multiplex amplification primer pairs from many different loci are combined in a single reaction and amplified simultaneously. Specifically, multiplex amplification reactions were performed in a 50 ⁇ l volume containing 100 ng of human genomic DNA, 0.5-1.0 ⁇ M of each primer, 1 unit of AmpliTaq Gold (Perkin-Elmer, Foster City, California) , 1 mM dNTPs, lOmM Tris/HCl (pH 8.3), 50 mM KCl , 5 mM MgCl 2 , and 0.001% gelatin.
  • Thermocycling was performed on a Tetrad (MJ Research, Watertown, Massachusetts) , with initial denaturation at 96°C for 10 minutes followed by 30 cycles of denaturation at 96°C for 30 seconds, primer annealing at 55°C for 2 minutes, and primer extension at 65°C for 2 minutes. After 30 cycles, a final extension reaction was carried out at 65°C for 5 minutes. Because the resulting amplification products were small, it was unnecessary to fragment them (as was done for the STSs in the SNP screen in Example 2, supra) .
  • the products were then biotin-labeled in a standard amplification reaction, by using T7 and T3 primers with biotin-labels at their 5 ' -ends (5 ' -biotin-TAATACGACTCACTATAGGGAGA-3 ' (SEQ ID NO:3), and 5 ' -biotin-AATTAACCCTCACTAAAGGG-3 ' (SEQ ID NO:4), respectively).
  • the reaction was performed with 1 ⁇ l of template DNA, 0.5-1.0 ⁇ M of labeled primer, 1 unit of AmpliTaq Gold (Perkin-Elmer, Foster City, California) , 100 ⁇ M dNTPs, lOmM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , and 0.001% Gelatin.
  • Thermocycling was performed with initial denaturation at 96°C for 10 minutes followed by 25 cycles of denaturation at 96°C for 30 seconds, primer annealing at 52 °C for 1 minute, and primer extension at 72 °C for 1 minute. After 25 cycles, a final extension reaction was carried out at 72°C for 5 minutes.
  • the amplification products from the various multiplex reactions for an individual were then pooled together. One-tenth of the pooled sample was denatured and used for chip hybridization. Chips were hybridized, washed, stained and scanned, as described in Example 2, supra .
  • thermocycling assays Although it is typically difficult to combine many thermocycling assays, this approach worked surprisingly well: of the 558 loci, 92% passed the detection test when amplification was performed in 24 sets of -23 loci; 90% passed when amplified in 12 sets of -46 loci; 85% passed when amplified in 6 sets of -92 loci; and 50% passed when amplified in a single set of 558 loci.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé d'amplification simultanée d'un grand nombre de séquences cibles à partir d'un acide nucléique matrice, et de marquage desdits produits d'amplification.
PCT/US1999/010417 1998-05-12 1999-05-12 Amplification muliplex d'adn a l'aide d'amorces chimeres WO1999058721A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39846/99A AU3984699A (en) 1998-05-12 1999-05-12 Multiplex dna amplification using chimeric primers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7657598A 1998-05-12 1998-05-12
US09/076,575 1998-05-12

Publications (1)

Publication Number Publication Date
WO1999058721A1 true WO1999058721A1 (fr) 1999-11-18

Family

ID=22132895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010417 WO1999058721A1 (fr) 1998-05-12 1999-05-12 Amplification muliplex d'adn a l'aide d'amorces chimeres

Country Status (2)

Country Link
AU (1) AU3984699A (fr)
WO (1) WO1999058721A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062064A2 (fr) * 2000-02-25 2001-08-30 Epigenomics Ag Procede pour detecter la methylation de cytosine dans des echantillons d'adn
GB2384308A (en) * 2002-01-15 2003-07-23 Matforsk Norwegian Food Res In Methods for nucleic acid amplification
WO2003060159A2 (fr) * 2002-01-15 2003-07-24 Matforsk Techniques d'amplification d'acide nucleique
FR2842534A1 (fr) * 2002-07-19 2004-01-23 Inst Nat Sante Rech Med Amplification multiplex quantitative a l'echelle d'un genome, et applications a la detection de remaniements genomiques
WO2004044240A2 (fr) * 2002-11-14 2004-05-27 November Aktiengesellschaft Procede d'identification parallele de differents acides nucleiques
WO2004113565A1 (fr) * 2003-06-20 2004-12-29 Serum Biomedical Institute Methode de production de molecules d'adn recombine
US20160010160A1 (en) * 2006-07-12 2016-01-14 Progenika Biopharma, S.A. Prognostic method
EP3378950A1 (fr) * 2017-03-21 2018-09-26 Sequencing Multiplex SLK Amplification et marquage simples en une étape

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018115A1 (fr) * 1990-05-16 1991-11-28 Life Technologies, Inc. Amplification de la transcription de sequences d'acides nucleiques activee par liaison du promoteur
WO1995011995A1 (fr) * 1993-10-26 1995-05-04 Affymax Technologies N.V. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
US5470723A (en) * 1993-05-05 1995-11-28 Becton, Dickinson And Company Detection of mycobacteria by multiplex nucleic acid amplification
WO1996041012A1 (fr) * 1995-06-07 1996-12-19 Genzyme Corporation Sequence d'amorce universelle pour une amplification multiplex de l'adn
US5624825A (en) * 1993-06-04 1997-04-29 Becton, Dickinson And Company Simultaneous amplification of multiple targets

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018115A1 (fr) * 1990-05-16 1991-11-28 Life Technologies, Inc. Amplification de la transcription de sequences d'acides nucleiques activee par liaison du promoteur
US5470723A (en) * 1993-05-05 1995-11-28 Becton, Dickinson And Company Detection of mycobacteria by multiplex nucleic acid amplification
US5624825A (en) * 1993-06-04 1997-04-29 Becton, Dickinson And Company Simultaneous amplification of multiple targets
WO1995011995A1 (fr) * 1993-10-26 1995-05-04 Affymax Technologies N.V. Reseaux de sondes d'acide nucleique sur des microplaquettes biologiques
WO1996041012A1 (fr) * 1995-06-07 1996-12-19 Genzyme Corporation Sequence d'amorce universelle pour une amplification multiplex de l'adn

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RYCHLIK: "PRIMING EFFICIENCY IN PCR", BIOTECHNIQUES, vol. 18, no. 1, 1 January 1995 (1995-01-01), pages 84, 86, 88/89, XP000486841, ISSN: 0736-6205 *
SHUBER A P ET AL: "A SIMPLIFIED PROCEDURE FOR DEVELOPING MULTIPLEX PCRs", PCR METHODS & APPLICATIONS, vol. 5, no. 5, 1 December 1995 (1995-12-01), pages 488 - 493, XP000546034, ISSN: 1054-9803 *
WANG D G ET AL: "Large-scale identification, mapping, and genotyping of single -nucleotide polymorphisms in the human genome", SCIENCE, vol. 280, 15 May 1998 (1998-05-15), pages 1077 - 1082, XP002089398, ISSN: 0036-8075 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524629B2 (en) 2000-02-25 2009-04-28 Epigenomics Ag Method for detecting cytosine methylation in DNA samples
WO2001062064A3 (fr) * 2000-02-25 2002-10-03 Epigenomics Ag Procede pour detecter la methylation de cytosine dans des echantillons d'adn
WO2001062064A2 (fr) * 2000-02-25 2001-08-30 Epigenomics Ag Procede pour detecter la methylation de cytosine dans des echantillons d'adn
GB2384308A (en) * 2002-01-15 2003-07-23 Matforsk Norwegian Food Res In Methods for nucleic acid amplification
WO2003060159A2 (fr) * 2002-01-15 2003-07-24 Matforsk Techniques d'amplification d'acide nucleique
GB2384308B (en) * 2002-01-15 2003-12-24 Matforsk Norwegian Food Res In Methods of nucleic acid amplification
WO2003060159A3 (fr) * 2002-01-15 2004-01-22 Matforsk Techniques d'amplification d'acide nucleique
FR2842534A1 (fr) * 2002-07-19 2004-01-23 Inst Nat Sante Rech Med Amplification multiplex quantitative a l'echelle d'un genome, et applications a la detection de remaniements genomiques
WO2004009846A1 (fr) * 2002-07-19 2004-01-29 Inserm Amplification multiplex quantitative a l'echelle genomique et applications dans la detection de rearrangements genomiques
WO2004044240A2 (fr) * 2002-11-14 2004-05-27 November Aktiengesellschaft Procede d'identification parallele de differents acides nucleiques
WO2004044240A3 (fr) * 2002-11-14 2004-07-29 November Ag Molekulare Medizin Procede d'identification parallele de differents acides nucleiques
WO2004113565A1 (fr) * 2003-06-20 2004-12-29 Serum Biomedical Institute Methode de production de molecules d'adn recombine
US7560528B2 (en) 2003-06-20 2009-07-14 Efthimios Ippikoglou Method of producing recombinant DNA molecules
US20160010160A1 (en) * 2006-07-12 2016-01-14 Progenika Biopharma, S.A. Prognostic method
EP3378950A1 (fr) * 2017-03-21 2018-09-26 Sequencing Multiplex SLK Amplification et marquage simples en une étape
WO2018172348A1 (fr) * 2017-03-21 2018-09-27 Sequencing Multiplex Sl Amplification et marquage faciles en une seule étape (eosal)

Also Published As

Publication number Publication date
AU3984699A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
US6703228B1 (en) Methods and products related to genotyping and DNA analysis
EP1124990B1 (fr) Gestion de la complexite et analyse d'adn genomique
Hacia et al. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays
US6972174B2 (en) Method for detecting single nucleotide polymorphisms (SNP's) and point mutations
EP1056889B1 (fr) Procedes associes a la determination d'un genotype et a l'analyse de l'adn
Twyman et al. Techniques patents for SNP genotyping
Hacia et al. Applications of DNA chips for genomic analysis
US20030082576A1 (en) High throughput polymorphism screening
US20060199183A1 (en) Probe biochips and methods for use thereof
Delahunty et al. Testing the feasibility of DNA typing for human identification by PCR and an oligonucleotide ligation assay.
Miller et al. High-density single-nucleotide polymorphism maps of the human genome
Twyman SNP discovery and typing technologies for pharmacogenomics
JP2011518568A (ja) Ｄｎａに基づくプロファイリングアッセイのための物質及び方法
Edwards et al. Plant genotyping by analysis of single nucleotide polymorphisms.
US20040023237A1 (en) Methods for genomic analysis
CA2273616A1 (fr) Methode de detection parallele de variation allelique
Black IV et al. Affordable assays for genotyping single nucleotide polymorphisms in insects
WO1999058721A1 (fr) Amplification muliplex d'adn a l'aide d'amorces chimeres
Wells et al. Genomics meets genetics: towards a mutant map of the mouse
Steinmetz et al. Combining genome sequences and new technologies for dissecting the genetics of complex phenotypes
US20040023275A1 (en) Methods for genomic analysis
Steinmetz et al. High-density arrays and insights into genome function
Drmanac et al. Sequencing by hybridization arrays
EP1567673A2 (fr) Procede de detection rapide de mutations et de polymorphismes nucleotidiques par chimiometrie
US20080026367A9 (en) Methods for genomic analysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase